


Program and Registration Guide

AASLD

The Liver Meeting® 2014
November 7-11
BOSTON, MA
Hynes Convention Center



Bridging Ideas to Action



AMERICAN ASSOCIATION FOR
THE STUDY OF LIVER DISEASES



Oct. 10 — advance registration discounts and housing deadline



AMERICAN ASSOCIATION FOR
THE STUDY OF LIVER DISEASES



The Liver Meeting® is held annually by the American Association for the Study of Liver Diseases (AASLD.)

AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. Our membership is international in scope and includes all professionals dedicated to hepatology and patient care.

We invite you to join AASLD, collaborate with your colleagues, and share in our discoveries.

To find out more about becoming a member, go to www.aasld.org/membership.

TABLE OF CONTENTS

Message From the President	5
Attendee Demographics.....	6-7
Registration and Housing Information.....	8-11
About Boston	11
The Liver Meeting® 2014 At-a-Glance	12-13
Ticketed Activities.....	15-29
• AASLD Postgraduate Course.....	20-21
AASLD Annual Meeting.....	30-47
• Poster and Plenary Sessions.....	31
• Parallel Sessions and Late-Breaking Abstracts.....	32
• Workshops, Lectures, and Symposia	33-40
• Special Interest Group (SIG) Programming.....	41-47
AASLD Pavilion	48
Exhibit Hall	49
Continuing Education Information.....	50-51
General Information.....	52-53

“ ...learn about the latest in hepatology research and patient care, and return to work ready to put new ideas into practice. ”



Adrian M. Di Bisceglie, MD, FACP
AASLD President

MESSAGE FROM THE PRESIDENT

Bridging Ideas to Action

On behalf of the American Association for the Study of Liver Diseases (AASLD), I cordially invite you to join us at The Liver Meeting® 2014 from Nov. 7 to 11 in Boston. This meeting brings together hepatologists from around the world to share their discoveries. You will learn about the latest in hepatology research and patient care, and return to work ready to put new ideas into practice.

We received 2,950 abstracts from 49 countries for consideration by our Scientific Program Committee. The very best of these will be presented at our plenary, parallel, and poster sessions (pp. 31-32).

New this year is an “Ethics and Humanities State-of-the-Art” lecture (p. 36), a session on “Value-based Medicine in Hepatology” (p. 35), and a look back at AASLD and the development of the field in “Four Decades of Progress in Hepatology,” the President’s Choice Lecture presented by Willis Maddrey, MD (p. 39).


Directed by Gyongyi Szabo, MD, PhD; Kyong-Mi Chang, MD; and Naga Chalasani, MD, the Postgraduate Course (pp. 20-21) will focus on “Clinical Implications of Inflammation and Immunity in Acute and Chronic Liver Disease.”

Distinguished speakers from around the world will explore this topic and provide comprehensive updates on newly available treatments, emerging therapies, and major scientific advancements.

AASLD continues its history of collaboratively presenting an array of other symposia with ASGE, ILTS, and NASPGHAN (p. 15, p. 16, p. 18).

The Liver Meeting® 2014 promises to be an excellent event with new research and practical resources you can put into action to advance your career. It is also a great opportunity to meet friends and connect with colleagues from around the world. I look forward to seeing you in Boston.

Sincerely,



Adrian M. Di Bisceglie, MD, FACP
AASLD President


ATTENDEE DEMOGRAPHICS

More than 9,500 hepatologists and hepatology health professionals from across the nation and around the world will gather in Boston at The Liver Meeting® to exchange the latest liver disease research, discuss treatment outcomes, and interact with colleagues at the annual must-attend event in the science and practice of hepatology.


Who Should Attend?

- Adult and pediatric hepatologists
- Clinical, basic, and translational researchers
- Specialists who diagnose and treat liver disease, including gastroenterologists, surgeons, pathologists, anesthesiologists, and radiologists
- Primary care physicians
- Nurses and allied health professionals
- Trainees and students in all of the disciplines listed above


WHO ATTENDS THE LIVER MEETING®




ATTENDEE PROFESSIONAL ACTIVITIES



ATTENDEE YEARS IN PRACTICE




ATTENDEE PARTICIPATION



Source: The Liver Meeting® 2013 Registration

Full descriptions, goals and objectives available online

ATTENDEES BY REGION



Color	Region	Total Count Per Region	% of the World
Dark Green	North America	5586	55%
Orange	Central America	18	0.20%
Blue	South America	400	4%
Grey	Europe	2017	20.5%
Light Blue	Central Asia	74	0.8%
Light Green	East & Southeast Asia	1198	12%
Brown	South Asia	106	1%
Medium Blue	Middle East	301	3%
Orange	Africa	205	2%
Dark Green	Australia & Oceania	145	1.5%
	World Total	10,050	100%

Source: The Liver Meeting® 2013 Registration

Program subject to change. Please confirm schedule in October through the “Liver Meeting” app, or onsite in the final printed Agenda.

REGISTRATION AND HOUSING INFORMATION

TAKE ADVANTAGE OF ADVANCE REGISTRATION DISCOUNTS Register by Oct. 10

The AASLD Annual Meeting is part of The Liver Meeting®. Registration for the Annual Meeting includes poster and parallel sessions; clinical updates in hepatitis C treatment with the Hepatitis Debrief and HCV Symposium; a full-year subscription to *LiverLearning*®; and more. See page 30 for complete details.

Additional events at The Liver Meeting® include ticketed activities and the AASLD Postgraduate Course. These are priced as marked within this guide.

Register Online

www.aasld.org/livermeeting

Use the code **LM14rb** when registering online.

Register Onsite

You can register on site in Hall A at the Hynes Convention Center during the following dates and times:

Thursday, November 6	2:00–8:00 pm
Friday, November 7	6:30 am–7:30 pm
Saturday, November 8	6:30 am–7:30 pm
Sunday, November 9	6:30 am–6:00 pm
Monday, November 10	6:30 am–6:00 pm
Tuesday, November 11	6:30 am–12:30 pm

LiverLearning®
THE OFFICIAL eLEARNING PORTAL OF AASLD

Free with
registration



Access content from The Liver Meeting® 2014 and more through *LiverLearning*®

Content from The Liver Meeting® 2014 will be available in this online library in December. A subscription to the service is free through Nov. 30, 2015, with your registration and includes more than 6,000 educational resources searchable by topic, type, speaker, and more.



Registration Confirmation

Your registration will be confirmed by email within 24 hours of processing the request. If confirmation is not received within two business days, please contact the AASLD Registration Center at 508-743-8541 or aasld@xpressreg.net.

Visa Requirements/Visa Waiver Program

Participants outside the U.S. may need to apply for a visa at the American Embassy, Consulate, or other visa-issuing office in their country of origin. To obtain a visa, you will need a letter of invitation, a valid passport, a photo ID, and a completed DS-156 form (nonimmigrant visa application form). To request an invitation letter, go to remote.aasld.org/eLetter_LM14/index.php.

Advance Registration Ends Oct. 10

Save money and secure your participation in popular ticketed activities by registering and booking housing in advance.

International participants seeking to travel to the U.S. under the Visa Waiver Program are now subject to enhanced security requirements. All eligible travelers who wish to travel through this program must apply for authorization using the Electronic System for Travel Authorization website, <https://esta.cbp.dhs.gov>.

To learn more about these requirements, visit the U.S. Department of State website, www.travel.state.gov.

Meeting Cancellations and Refunds

A written cancellation and refund request is required for all cancellations. Those whose requests are received on or before Oct. 17 will be eligible for a full refund of registration fees.* Those whose requests are received between Oct. 18 and Nov. 5 will be subject to a \$50 administrative fee. Those whose cancellations are received on or after Nov. 6, 2014, will not be refunded. Fees will not be refunded for no-shows.

* Refunds will not be given for Meet-the-Professor Luncheons or Early Morning Workshops unless the seat can be resold.

Questions?

Customer Service Center:
508-743-8541
(Toll-free 866-672-3797)

E-mail: aasld@xpressreg.net

OFFICIAL HOTELS AND RATES

Online: www.aasld.org/livermeeting Email: aasld@onpeak.co

Phone: (888) 254-0939 US Toll-free / (312) 527-7300 Local

Group Booking: Any group requesting 20 or more rooms should email a request to aasld@onpeak.co. onPeak will follow up to assist with securing all group housing requests.

**Rates do not include current tax of 14.45% or applicable surcharges. Subject to change.*

- 1. John B. Hynes Veterans Memorial Convention Center**
900 Boylston Street *Connected*
- 2. Boston Park Plaza Hotel & Towers**
\$234 Single/Double
50 Park Plaza 6 blocks
- 3. Colonnade Boston**
\$314 Single/Double
120 Huntington Avenue 1 block
- 4. Copley Square Hotel**
\$325 Single/Double
47 Huntington Avenue 2 blocks
- 5. Courtyard Boston Copley Square**
\$249 Single/Double
88 Exeter Street 2 block
- 6. Courtyard Boston Tremont Hotel**
\$255 1 Bed, \$275 Single/Double 2 Beds
275 Tremont Street 1.6 miles
- 7. Doubletree by Hilton Downtown Boston**
\$276 Single/Double
821 Washington Street 1.6 miles
- 8. Fairmont Copley Plaza Boston**
\$334 Standard, \$369 Deluxe
138 St. James Avenue 4 blocks
- 9. Hilton Boston Back Bay**
\$296 Single/Double
40 Dalton Street 0.5 blocks

- 10. Hyatt Regency Boston**
\$305 Single/Double
1 Ave de Lafayette 1 mile
- 11. Langham Hotel Boston**
\$299 Single/Double
250 Franklin Street 2 miles
- 12. Liberty Hotel**
\$369 Single/Double
215 Charles Street 1.5 miles
- 13. Loews Boston Back Bay**
\$319 Single/Double
350 Stuart Street 4 blocks
- 14. Marriott Copley Place**
\$320 Single/Double
110 Huntington Avenue 1.5 blocks

- 15. Midtown Hotel**
\$169 Single/Double 2 Beds
220 Huntington Avenue 0.5 miles
- 16. Omni Parker House Hotel**
\$279 Single/Double
60 School Street 1.4 miles
- 17. Revere Hotel Boston Common**
\$278 Single/Double
200 Stuart Street 1.3 miles
- 18. Sheraton Boston Hotel**
\$295 Single/Double
39 Dalton Street *Connected*
- 19. W Boston**
\$329 Single/Double
100 Stuart Street 1 mile
- 20. Westin Copley Place**
\$315 Single/Double
10 Huntington Avenue 3 blocks



Full descriptions, goals and objectives available online

HOUSING

Reserve a Hotel

We highly recommend making your hotel reservations when you register for The Liver Meeting® 2014. All hotel reservations must be made through onPeak, AASLD's official housing provider.

Online

Reserve at www.aasld.org/livermeeting.

Phone

(U.S.) 888-254-0939

(International): 1-312-527-7300

Hotel Reservations and Cancellations

Hotel confirmations will be emailed within 72 hours of booking. Individual reservations must be canceled at least 72 hours before the day of arrival to avoid losing your deposit. For groups or affiliates holding 10 or more rooms, the deposit is *nonrefundable* and *nontransferable* after Friday, Sept. 12, 2014.


ABOUT BOSTON

Boston is a compact city of distinct neighborhoods with a walkable downtown area and an almost European feel. Explore the quaint colonial architecture of Beacon Hill, sample a treat in the Italian North End, explore the boutiques along Newbury Street in the Back Bay, or spend some time in the academic district of Cambridge. The Freedom Trail, a two-and-a-half-mile red brick path, will wind you through the downtown area to visit 16 historically important sites, including Faneuil Hall, the Paul Revere House, and the USS Constitution. The dining scene goes way beyond Beantown's baked beans with plentiful fine-dining options, beloved ice cream parlors, and famous breweries and bars. One of the oldest cities in America, you'll find history and culture around every bend in Boston.



THE LIVER MEETING® 2014 AT-A-GLANCE

The Liver Meeting® app makes it easy to plan your agenda and navigate the meeting. Search “Liver Meeting” in the App Store (for your Apple device) or in Google Play (for your Android device).


 Indicates that an additional fee is required for this session.


THURSDAY, NOVEMBER 6

2:00–8:00 pm Registration **p. 8**


FRIDAY, NOVEMBER 7

6:30 am–7:30 pm Registration **p. 8**


7:55 am–3:00 pm AASLD/ASGE Endoscopy Course: Endoscopy in the Management of Patients With Liver Disease **p. 15** 


8:00 am–2:45 pm AASLD/ILTS Transplant Course: Catalysts for Innovation in Liver Transplantation **p. 16** 

10:00 am–Noon Career Development Workshop: Building Your Hepatology Career From Fellow to Faculty and Beyond **p. 17** 

Noon–3:00 pm AASLD/NASPGHAN Pediatric Symposium: The Kidney in the Child With Chronic Liver Disease **p. 18** 


12:30–2:45 pm Competency Training Workshop **p. 33**

12:30–3:30 pm Clinical Research Workshop: Clinical Trials From Concept to Implementation **p. 19** 

3:30–7:30 pm Postgraduate Course: Clinical Implications of Inflammation and Immunity in Acute and Chronic Liver Disease **pp. 20-21** 


SATURDAY, NOVEMBER 8

6:30 am–7:30 pm Registration **p. 8**


8:00 am–5:00 pm Postgraduate Course: Clinical Implications of Inflammation and Immunity in Acute and Chronic Liver Disease **pp. 20-21** 

9:00 am–Noon Liver Transplantation and Surgery SIG Program: Outreach in Liver Transplant **p. 41**

SATURDAY, NOVEMBER 8 (CONTINUED)

12:20–1:40 pm Meet-the-Professor Luncheons **p. 22** 

2:00–7:30 pm Poster Session I (authors available 5:30 - 7:00 pm) **p. 31**

3:30–7:00 pm Transplant Surgery Workshop: Management of Comorbidities for Successful Surgical Procedures, Hepatic Resections, and Transplant **p. 23** 


5:00–7:30 pm Exhibits Open **p. 49**

5:00–7:30 pm Opening Reception


5:15–6:15 pm Business Meeting (AASLD members only)


SUNDAY, NOVEMBER 9

6:30 am–6:00 pm Registration **p. 8**

6:45–7:45 am Early Morning Workshop **pp. 24-26** 

8:00–9:30 am Transplant Plenary I **p. 31**

8:00 am–Noon Basic Research Workshop: Liver Fibrosis **p. 27** 

8:00 am–1:30 pm Hepatology Associates Course **p. 28** 

8:00 am–5:30 pm Poster Session II (authors available 12:30 - 2:00 pm) **p. 31**

9:30–10:00 am Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture: Living Donor Liver Transplantation: Has It Fulfilled Its Promise? **p. 34**

9:30 am–3:00 pm Exhibit Opens **p. 49**

10:00–11:30 am Emerging Trends Symposium: Acute on Chronic Liver Failure **p. 34**

10:30 am–Noon Transplant Plenary II **p. 31**

Noon–12:30 pm Hans Popper Basic Science State-of-the-Art Lecture: Induced Pluripotent Stem Cells and Their Use in the Study of Liver Disease and Development **p. 35**


SUNDAY, NOVEMBER 9 (CONTINUED)

1:00–3:00 pm	 Value-based Medicine in Hepatology p. 35
1:15–2:45 pm	Keeping Up With Maintenance of Certification (MOC): A Comprehensive Review of the ABIM MOC Program p. 36
2:00–2:30 pm	 Ethics and Humanities State-of-the-Art Lecture: A Toxic History of Modernity – From Black Bile to Living on Light p. 36
2:45–3:00 pm	Distinguished Clinician Educator/Mentor Award Presentation
3:00–4:30 pm	General Hepatology Update p. 37
3:00–4:30 pm	Parallel Sessions p. 32
4:45–6:15 pm	Parallel Sessions p. 32
4:45–6:45 pm	Hepatotoxicity SIG Program: Pharmacogenomic Approaches in DILI Research p. 42
4:45–7:00 pm	Pediatric Liver Disease and Cholestatic Liver Disease Joint SIG Program: Controversies in the Management of PSC in Children and Adults p. 43
4:45–7:00 pm	Hepatobiliary Neoplasia SIG Program: Primary Liver Carcinomas With Intermediate/Stem Cell Features: Microscopic to Genomic Evidence and Back p. 42
4:45–7:45 pm	Liver Cell Biology in Hepatic Disease and Liver Fibrosis Joint SIG Program: The Cell Biology of Hepatic Disease p. 44

MONDAY, NOVEMBER 10

6:30 am–6:00 pm	Registration p. 8
6:45–7:45 am	Early Morning Workshops pp. 24-26
8:00–9:30 am	Basic Plenary I p. 31
8:00 am–5:30 pm	Poster Session III (authors available) 12:30–2 pm p. 31
9:30–10:00 am	Distinguished Service and Achievement Award Presentations
9:30 am–3:00 pm	Exhibits Open p. 49
10:00–10:30 am	Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture: Drug-Induced Liver Injury p. 37


MONDAY, NOVEMBER 10 (CONTINUED)

11:00 am–12:30 pm	Clinical Plenary p. 31
11:00 am–12:30 pm	Advances for Practitioners: New Treatments for Hepatitis C p. 38
11:45 am–1:15 pm	Professional Development Workshop: Choices and Career Paths in Hepatology p. 29 
2:00–4:00 pm	Global Forum: Health Disparities in Liver Disease – The Haves and Have-Nots p. 38
2:15–2:45 pm	President's Choice: Four Decades of Progress in Hepatology p. 39
2:45– 4:30 pm	Presidential Address and Late-breaking Abstracts p. 32
3:00–4:30 pm	Parallel Sessions p. 32
4:45–6:15 pm	HCV Symposium: What's #Trending in Hepatitis C? p. 39
4:45–6:15 pm	Parallel Sessions p. 32
4:45–6:45 pm	Portal Hypertension SIG Program: Noninvasive Methods to Stratify Risk in Patients With Compensated Cirrhosis Portal Hypertension p. 45
4:45–7:00 pm	Liver Fibrosis SIG and Steatosis and Steatohepatitis SIG Joint Program: Immunity and Lipids as New Drivers in Inflammation and Fibrosis of Nonalcoholic Steatohepatitis p. 46
4:45–7:30 pm	Acute on Chronic Liver Failure SIG Program: Renal Dysfunction in Cirrhosis: Should We Change the Way We Manage These Patients? p. 47
4:45–7:50 pm	Hepatitis B SIG Program: The Next Generation of HBV Therapy: From Discovery to Cure p. 47

TUESDAY, NOVEMBER 11

6:30 am–12:30 pm	Registration p. 8
6:45–7:45 am	Early Morning Workshops pp. 24-26
8:00–9:30 am	Hepatitis Plenary p. 31
8:00 am–Noon	Poster Session IV (authors available 10:30 am – Noon) p. 31
9:45–10:30 am	Hepatitis Debrief p. 40
10:30–11:00 am	Leon Schiff State-of-the-Art Lecture: Benign Tumors of the Liver p. 40
11:15 am–12:45 pm	Parallel Sessions p. 32

GET THE MOST FROM YOUR EXPERIENCE AT THE LIVER MEETING® 2014



Use The Liver Meeting® App

Navigate the meeting and access the most comprehensive event information with this free app.

Take control of your meeting experience (and your time). Plan in advance by searching all educational sessions and add them to your personal agenda. You can also plan visits to the exhibit hall, view convention center floor plans, complete CME session evaluations, and more.

Search “Liver Meeting” in the App Store (for your Apple device) or in Google Play (for your Android device.)

Use Social Media

Social media lets you interact with speakers and attendees at the meeting and beyond.



www.facebook.com/AASLDNews

Like us on Facebook.



www.twitter.com/AASLDNews

Use the hashtag #liver14 to join the conversation about The Liver Meeting® 2014.



www.youtube.com/AASLDvideo

Find videos from The Liver Meeting® and from other AASLD activities.



www.aasld.org/linkedin

Invite your colleagues to connect with you individually and join the AASLD group.



www.instagram.com/aasld

Follow AASLD to see and share event photos.

Use LiverLearning®


Content from The Liver Meeting® 2014 will be available in this online library in December. A subscription is free through Nov. 30, 2015, with your registration and includes more than 6,000 educational resources searchable by topic, type, speaker, and more.

LiverLearning®
THE OFFICIAL eLEARNING PORTAL OF AASLD

Go to liverlearning.aasld.org

TICKETED ACTIVITIES

The following activities are not part of the AASLD Annual Meeting registration and require additional fees.



AASLD/ASGE Endoscopy Course

Endoscopy in the Management of Patients With Liver Disease

Friday, Nov. 7 • 7:55 am–3 pm

Course Directors: Marta L. Davila, MD, AGAF, FACG, FASGE; Michael B. Wallace, MD, MPH, FASGE



CME 7.0 CME Credits


Enhance your working knowledge of state-of-the-art practices in the endoscopic management of patients with advanced cirrhosis, biliary tract disease, chronic cholestatic conditions, and other liver diseases — both before and after liver transplantation. The course will cover fundamental issues related to the quality and safety of endoscopic practice in the patient with liver disease, including safe administration of sedation as it relates to disease-specific issues such as coagulopathy. Participants will learn about the management and prevention of variceal hemorrhage, as well as advanced endoscopic techniques such as cholangioscopy for biliary disease.

Upon completion of this activity, participants will be able to:

- Select patients with liver disease who may undergo endoscopic procedures.
- Identify standards of care for treating portal hypertensive conditions, including esophageal and gastric varices and vascular ectasia.
- Choose appropriate testing and staging procedures for patients with biliary strictures and suspected cholangiocarcinoma.
- Recommend appropriate endoscopic procedures for the management of biliary complications of transplantation.

	BEFORE 10/10	AFTER 10/10
Member	\$255	\$305
Trainee Member	\$85	\$135
Hepatology Associate Member	\$85	\$135
Nonmember	\$390	\$440
Trainee Nonmember	\$105	\$155
Hepatology Associate Nonmember	\$105	\$155
Student	\$85	\$135

TICKETED ACTIVITIES



AASLD/ILTS Transplant Course

Catalysts for Innovation in Liver Transplantation

Friday, Nov. 7 • 8:00 am–2:45 pm



Course Directors: Paul J. Gaglio, Sr., MD; Miguel Navasa, MD; John F. Renz, MD, PhD

CME 6.5 CME Credits

CE 5.0 Contact Hours


With the worldwide application of liver transplantation, the need for a stimulating clinical and translational research environment has never been greater. However, a number of U.S. donor and recipient metrics over the past decade — including wait-list mortality, donor utilization, and application of living donation — suggest a systemic plateau. This course will help you recognize new opportunities while identifying clinical and scientific catalysts for innovation in transplantation.

Upon completion of this activity, participants will be able to:

- Review the current practice of liver transplantation and identify potential new clinical opportunities.
- Identify recent advancements in immunosuppression, tolerance induction, and therapeutics that demonstrate substantial promise.
- Assess current risk practices within the specialty of liver transplantation.
- Identify policies, processes, and practices that impede or promote innovation.
- Propose novel metrics and processes to foster efficient translational research and program development within the current health care environment.

	BEFORE 10/10	AFTER 10/10
Member	\$190	\$240
Trainee Member	\$115	\$165
Hepatology Associate Member	\$115	\$165
Nonmember	\$275	\$325
Trainee Nonmember	\$125	\$175
Hepatology Associate Nonmember	\$125	\$175
Student	\$115	\$165

TICKETED ACTIVITIES



Career Development Workshop

Building Your Hepatology Career from Fellow to Faculty and Beyond

Friday, Nov. 7 • 10:00 am–Noon

Course Directors: Michael Fuchs, MD, PhD; Mark W. Russo, MD, MPH

CME Not Available

This workshop is designed to assist clinical and research trainees as well as junior faculty members who are pursuing careers in hepatology in a changing health care landscape. Participants will have the opportunity to interact with leaders in the field to appreciate the different career pathways hepatology can offer.

Upon completion of this activity, participants will be able to:


- Describe the fellowship training tracks available in hepatology and transplant hepatology.
- Identify the best fit for a mentor.
- Apply skills essential to building a successful career.
- Recognize future trends in hepatology in a changing health care system.

	BEFORE 10/10	AFTER 10/10
Member	\$40	\$50
Trainee Member	No Charge	\$50
Hepatology Associate Member	\$40	\$50
Nonmember	\$40	\$50
Trainee Nonmember	\$40	\$50
Hepatology Associate Nonmember	\$40	\$50
Student	\$40	\$50



Program subject to change. Please confirm schedule in October through the “Liver Meeting” app, or onsite in the final printed Agenda.

TICKETED ACTIVITIES



AASLD/NASPGHAN Pediatric Symposium

The Kidney in the Child With Chronic Liver Disease

Friday, Nov. 7 • Noon–3:00 pm

Course Directors: Jean P. Molleston, MD; Ronen Arnon, MD



CME 3.0 CME Credits


Examine the kidney’s role in children with chronic liver disease. Experts in pediatrics, internal medicine, nephrology, and hepatology will discuss hepatorenal syndrome types I and II, and long-term renal function after liver transplantation. Coverage includes diseases that affect both the liver and kidney, requiring dual transplantation. Participants will also receive updates on cystic disease of the liver and kidney.

Upon completion of this activity, participants will be able to:

- Apply knowledge of the pathophysiology of renal dysfunction in chronic liver disease when managing patients with cirrhosis and its complications.
- Recognize long-term renal outcomes after liver transplantation.
- Identify the role of liver/kidney combined transplantation in managing several systemic diseases.
- Enhance knowledge of disease mechanisms in polycystic liver and kidney diseases.

	BEFORE 10/10	AFTER 10/10
Member	\$165	\$215
Trainee Member	\$85	\$135
Hepatology Associate Member	\$85	\$135
Nonmember	\$270	\$320
Trainee Nonmember	\$105	\$155
Hepatology Associate Nonmember	\$105	\$155
Student	\$85	\$135

TICKETED ACTIVITIES



Clinical Research Workshop

Clinical Trials From Concept to Implementation

Friday, Nov. 7 • 12:30–3:30 pm

Course Directors: Marc G. Ghany, MD; Andrew Muir, MD; Averell H. Sherker, MD

CME Not Available

Aspiring clinical investigators will get an overview of the nuts and bolts of conducting a clinical trial, beginning with the research question, ending with enrollment, and covering all of the steps in between. The program will emphasize four broad topics: development of a protocol, funding sources for clinical research, regulatory issues, and assembly and management of a research team. Seven breakout sessions will provide further specifics.


Upon completion of this activity, participants will be able to:

- Apply the basic requirements to conduct clinical research.
- Enhance their role as an effective member of a research team.
- Identify common pitfalls that lead to failure in clinical research.

	BEFORE 10/10	AFTER 10/10
Member	\$55	\$65
Trainee Member	No Charge	\$50
Hepatology Associate Member	\$40	\$50
Nonmember	\$60	\$70
Trainee Nonmember	\$45	\$55
Hepatology Associate Nonmember	\$45	\$55
Student	\$40	\$50



THE AASLD POSTGRADUATE COURSE



Gyongyi Szabo
MD, PhD



Kyong-Mi Chang
MD



Naga P. Chalasani
MD

Clinical Implications of Inflammation and Immunity in Acute and Chronic Liver Disease: Advances in Diagnosis, Treatment, and Clinical Practice

Friday, Nov. 7 • 3:30–7:30 pm and Saturday, Nov. 8 • 8:00 am–5:00 pm

Course Directors: Gyongyi Szabo, MD, PhD; Kyong-Mi Chang, MD; Naga P. Chalasani, MD

CME 12.0 CME Credits

CE 10.0 Contact Hours

While inflammation and immunity are key elements in most acute and chronic liver diseases, the volume and complexity of information on this topic can be overwhelming. This comprehensive update will provide information on the latest treatments and emerging therapies while exploring the roles inflammation and immunity play in liver disease.

Upon completion of this activity, participants will be able to:

- Discuss the role of immune cells and inflammation in different etiologies of liver diseases.
- Describe the triggers and mechanisms of immune activation and inflammation in the liver.
- Identify potential therapeutic targets that intervene with immune and inflammation-mediated liver damage.
- Improve clinical practice by understanding the consequences of chronic inflammation in the progression of liver disease.


Friday 3:30–4:55 pm	Session I: The ABCs of Inflammation and Immunity in the Liver
	Inflammation and Immunity: A Primer for Hepatologists
	Clinical Consequences of Liver Inflammation: An Overview
	Liver Disease and Immune Cells: The Pathologist's View
5:10–6:10 pm	Session II: Acute Liver Injury: Dead Cells and Surviving Patients
	Sterile Inflammation in Acute Liver Injury: Myth or Mystery?
	Acute Liver Failure or Multiorgan Dysfunction Syndrome?
6:10–7:30 pm	Session III: Chronic Hepatitis: Controlling Infection or Causing Inflammation?
	Immunity and Inflammation in Chronic Hepatitis B in Adults – When to Treat?
	Immunity and Inflammation in Chronic Hepatitis C – Does Treatment Help?
	Mechanisms and Strategies of Antiviral Therapies in HCV

THE AASLD POSTGRADUATE COURSE

Saturday 8:00–10:00 am	Session IV: Steatohepatitis: ASH and NASH
	Immune-Mediated Liver Damage: The Troublemakers and the Peacekeepers
	Alcoholic and Nonalcoholic Steatohepatitis: Similarities and Key Differences in Treatment Options
	Immune Activation in the Metabolic Syndrome - Implications for the Clinician
	Growing Kids and Growing Concerns: Pediatric NAFLD
	Clinical Management, Current and Emerging Pharmacotherapies in NAFLD and NASH
Trimming the Fat: The Liver and Beyond	
10:20 am–12:20 pm	Session V: Autoimmunity and Immune Tolerance in the Liver
	Clinical Implications of Autoimmunity - Autoimmune Hepatitis and Overlap Syndrome
	Autoimmunity in Cholestatic Liver Disease - New Concepts and Therapies
	Biliary Atresia: Update on Investigations of Pathogenesis and Outcomes
	Autoimmunelike Drug-Induced Liver Injury Case Presentations
Liver Transplantation and Allograft Rejection	
12:20–1:40 pm	Meet-the-Professor Luncheons (separate ticket required, see page 22)
1:40–3:10 pm	Session VI: Reversibility of Chronic Liver Disease
	Liver Fibrosis: The Toll of Inflammation
	Acute on Chronic Liver Disease: Is There Liver-Gut-Brain Crosstalk?
	Debate: What Causes Hepatorenal Syndrome?
	Emerging Therapies Targeting Inflammation in Liver Disease
3:30–4:55 pm	Session VII: From the Past to the Future: Targeted Therapies
	When Immune Surveillance Fails: Managing Hepatocellular Cancer
	Emerging Trends in Hepatology Practice: Science-Driven Care of Liver Diseases and Cancer - From Stem Cells to Genomics
	In Search of the Magic Bullet: Can Liver Inflammation and Fibrosis Be Reversed With Medications?
	Ending Liver Inflammation and Curing Liver Disease: From Test Tubes to Patients

	BEFORE 10/10	AFTER 10/10
Member	\$450	\$550
Trainee Member	\$190	\$290
Hepatology Associate Member	\$190	\$290
Nonmember	\$670	\$770
Trainee Nonmember	\$270	\$370
Hepatology Associate Nonmember	\$270	\$370
Student	\$190	\$290

TICKETED ACTIVITIES



Sessions sell out quickly. Register early.

Saturday, Nov. 8

12:20–1:40 pm


Meet-the-Professor Luncheons

Moderated by subject experts, these luncheons provide attendees the unique opportunity to explore a wide variety of topics in small-group settings.

MTP – 1:	Hepatitis B: Treatment Choice and Monitoring for Response and Resistance Norah Terrault, MD and Harry L.A. Janssen, MD, PhD
MTP – 2:	Hepatitis C: What to Offer to Difficult-to-Treat Patients Kris V. Kowdley, MD and Mark S. Sulkowski, MD
MTP – 3:	Hepatitis C: Management of Pre- and Post-Liver Transplantation Paul Y. Kwo, MD and Kymberly Watt, MD
MTP – 4:	HCC: Management from a Hepatologist's Perspective Laura M. Kulik, MD and K. Rajender Reddy, MD
MTP – 5:	Renal Failure in Cirrhosis – Is It Pre-Renal, AKI, or HRS? Florence Wong, MD and Josh Levitsky, MD
MTP – 6:	Portal and Mesenteric Vein Thrombosis in Cirrhosis Patrick S. Kamath, MD and Guadalupe Garcia-Tsao, MD
MTP – 7:	Bone Disease in Liver Disease – Don't Forget About It Marion G. Peters, MD and Herbert L. Bonkovsky, MD
MTP – 8:	Management of Gastric Varices: Beta-Blockers, Glue, or TIPS Shiv Kumar Sarin, MD and Stephen H. Caldwell, MD
MTP – 9:	How to Work Up a Patient With Suspected NAFLD Stephen A. Harrison, MD and Miriam B. Vos, MD
MTP – 10:	Portopulmonary Hypertension and New Pulmonary Vasodilators Michael J. Krowka, MD and Michael B. Fallon, MD
MTP – 11:	Hepatic Encephalopathy: Current and Future Treatments Jasmohan S. Bajaj, MD and Marwan S. Ghabril, MD
MTP – 12:	DILI: Lessons Learned From the DILIN and the Spanish DILI Registry Raul J. Andrade, MD, PhD and Robert J. Fontana, MD
MTP – 13:	Noninvasive Assessment of Liver Fibrosis and Liver Function Jayant A. Talwalkar, MD and Marc G. Ghany, MD
MTP – 14:	Alcoholic Liver Disease: Approaches to Diagnosis and Treatment of Moderate and Severe Alcoholic Hepatitis Michael R. Lucey, MD and Mack C. Mitchell, MD
MTP – 15:	What's New in Pediatric Liver Disease in 2014? Jean P. Molleston, MD and Kathleen B. Schwarz, MD

	BEFORE 10/10	AFTER 10/10
Member	\$50	\$60
Nonmember	\$50	\$60

TICKETED ACTIVITIES



Transplant Surgery Workshop

Management of Comorbidities for Successful Surgical Procedures, Hepatic Resections, and Transplant

Saturday, Nov. 8 • 3:30–7:00 pm

Course Directors: Kenneth Chavin, MD; John Magee, MD

CME 3.5 CME Credits


Improve patient care and outcomes by increasing competence in selecting appropriate management of comorbidities commonly encountered in patients with ESLD who are undergoing a surgical intervention including hepatic resection and transplant.

Upon completion of this activity, participants will be able to:

- Identify risk factors and the management of metabolic syndrome and its effect on surgical outcomes.
- Identify risk factors and the management of cardiovascular and pulmonary diseases and their effect on surgical outcomes.
- Recommend futile surgery for patients with liver disease and the role of the ICU in surgical outcomes.

	BEFORE 10/10	AFTER 10/10
Member	\$95	\$145
Trainee Member	\$80	\$130
Hepatology Associate Member	\$80	\$130
Nonmember	\$115	\$165
Trainee Nonmember	\$85	\$135
Hepatology Associate Nonmember	\$85	\$135
Student	\$80	\$130

TICKETED ACTIVITIES



Space is limited. Register early.

Sunday, Nov. 9
6:45–7:45 am
Monday, Nov. 10
6:45–7:45 am
Tuesday, Nov. 11
6:45–7:45 am

Early Morning Workshops

These highly popular small-group sessions provide participants with an opportunity to interact with two experts in a specialized area of liver disease or investigation. Early Morning Workshops consist of two categories: basic research and clinical management. The registration fee is per workshop, per day.

Sunday	Basic EMW
EMW – 1:	Alcoholic Liver Disease: Mechanisms and Therapeutic Targets Vijay Shah, MD and Pranoti Mandrekar, PhD
EMW – 2:	Stellate Cell Biology Don C. Rockey, MD and Jonathan A. Dranoff, MD
EMW – 3:	Triggers of Fibrosis in NASH Natalie Torok, MD and Detlef Schuppan, MD, PhD
EMW – 4:	Cholestasis and Cholangiocyte Pathobiology Gianfranco Alpini, PhD and Laura Bull, PhD
EMW – 5:	Microbiome and Gut Permeability in Liver Disease Bernd Schnabl, MD and Gavin E. Arteel, PhD
EMW – 6:	Animal Models of NAFLD Frank A. Anania, MD and David Cohen, MD
	Clinical EMW
EMW – 7:	New Drugs for Hepatitis B in the Pipeline Anna S. F. Lok, MD and Tram T. Tran, MD
EMW – 8:	Reactivation of Hepatitis B During Chemo/Immunosuppressive Therapy Harry L.A. Janssen, MD, PhD and Robert P. Perrillo, MD
EMW – 9:	Controversies in Pediatric ALF Ronald J. Sokol, MD and David Rudnick, MD, PhD
EMW – 10:	Cardiopulmonary Complications of Liver Disease in Children and Adults Saul J. Karpen, MD, PhD and John C. Bucuvalas, MD
EMW – 11:	Causality Assessment and Autoimmunity in Hepatotoxicity Paul B. Watkins, MD and Victor J. Navarro, MD
EMW – 12:	New Anti-tumor Agents in Development for HCC Gregory J. Gores, MD and Amit Singal, MD
EMW – 13:	Quality Improvement in Management of Patients With Liver Disease Michael Volk, MD and Fasiha Kanwal, MD
EMW – 14:	Acute on Chronic Liver Failure Ram M. Subramanian, MD and Anne M. Larson, MD

TICKETED ACTIVITIES


Monday	Basic EMW
EMW - 15:	Management of Coagulopathies in Chronic Liver Disease Stephen H. Caldwell, MD and R. Todd Stravitz, MD
EMW - 16:	Parenchymal and Immune Cell Interactions in Liver Disease Fabio Marra, MD, PhD and Laura E. Nagy, PhD
EMW - 17:	Autophagy in ASH and NASH Mark J. Czaja, MD and John J. Lemasters, MD, PhD
EMW - 18:	Cell Death and Sterile Inflammation in Liver Disease Wajahat Z. Mehal, MD and Ariel Feldstein, MD
EMW - 19:	Noncoding RNAs in Liver Disease Gregory J. Gores, MD and Shashi Bala, PhD
EMW - 20:	Viral Hepatitis: Immunology in Pathogenesis Kyong-Mi Chang, MD and Barbara Rehermann, MD
Clinical EMW	
EMW - 21:	Many Faces of PFIC Jorge A. Bezerra, MD and Binita M. Kamath, MB BChir
EMW - 22:	Herbal Hepatotoxicity Leonard B. Seeff, MD and Mark G. Clemens, PhD
EMW - 23:	Emerging Therapies for Management of NASH Naga P. Chalasani, MD and Manal F. Abdelmalek, MD
EMW - 24:	2014: Clinical Update in Alcoholic Liver Disease Philippe Mathurin, MD, PhD and Timothy R. Morgan, MD
EMW - 25:	What Else to Come in HCV Therapy? Jean-Michel Pawlotsky, MD, PhD and Paul J. Pockros, MD
EMW - 26:	NASH: Diagnosis and Management Arthur J. McCullough, MD and Rohit Kohli, MD
EMW - 27:	NASH: Comorbidities Kathleen E. Corey, MD, MPH and Richard M. Green, MD
EMW - 28:	Peritransplant Management of HCV Infection Norah Terrault, MD and Jacqueline G. O'Leary, MD

TICKETED ACTIVITIES

Tuesday		Basic EMW
EMW – 29:	Sinusoidal Endothelial Cells and Fibrogenesis Laurie D. DeLeve, MD, PhD and Vijay Shah, MD	
EMW – 30:	Stem Cells and Regeneration in Liver Disease Sanjeev Gupta, MD and Lopa Mishra, MD	
EMW – 31:	Novel Molecular Mechanisms and Targets in HCC TBD	
		Clinical EMW
EMW – 32:	Use of Livertox and Use of EMR Mining in Hepatotoxicity Herbert L. Bonkovsky, MD and Robert J. Fontana, MD	
EMW – 33:	When Can You Withdraw Treatment for Hepatitis B? Natalie H. Bzowej, MD and George V. Papatheodoridis, MD	
EMW – 34:	What’s New for HIV/HCV Co-infected Patients in 2014? Andrea Cox, MD, PhD and Kenneth E. Sherman, MD, PhD	
EMW – 35:	Streamlining HCV Therapy in Treatment of Naïve Patients Margaret J. Koziel, MD and Donald M. Jensen, MD	
EMW – 36:	Streamlining HCV Therapy in Previous Treatment Failures and Nonresponders Marc G. Ghany, MD and Patrick Marcellin, MD, PhD	
EMW – 37:	Ethical Considerations in the Practice of Hepatology – Explaining Risks to Subjects Adrian Reuben, MBBS, FRCP, FACG and Andrew I. Aronsohn, MD	
EMW – 38:	Update on Autoimmune Hepatitis Michael P. Manns, MD and John M. Vierling, MD, FACP	
EMW – 39:	TIPS in Cirrhosis: Benefits and Complications Florence Wong, MD and Theo Heller, MD	
EMW – 40:	Controversies and Updates in PSC and PBC Cynthia Levy, MD and Keith D. Lindor, MD	
EMW – 41:	Special Consideration in Private Practice for the Hepatology Provider Mitchell L. Shiffman, MD and Savant Mehta, MD	

	BEFORE 10/10	AFTER 10/10
Member	\$25	\$35
Nonmember	\$45	\$55
Student	\$25	\$35

TICKETED ACTIVITIES



Basic Research Workshop

Liver Fibrosis

Sunday, Nov. 9 • 8:00 am–Noon

Course Directors: Robert F. Schwabe, MD; Ekihiro Seki, MD, PhD

CME 4.0 CME Credits


Antifibrotic drugs remain unsuccessful in the treatment of liver fibrosis—a key factor in the long-term outcome of chronic liver disease. Learn about the underlying mechanisms and pathways of liver fibrosis and gain an understanding of antifibrotic strategies, animal models, and translation into clinical trials.

Upon completion of this activity, participants will be able to:

- Develop concepts and therapies that directly prevent or reverse liver fibrosis.
- Review relevant fibrogenic cell populations and focus on mechanisms that regulate the activation of hepatic stellate cells, the main fibrogenic cell type of the liver.
- Discuss animal models of liver fibrosis and how they can be employed to develop translational approaches for the treatment of liver fibrosis.

	BEFORE 10/10	AFTER 10/10
Member	\$95	\$145
Trainee Member	\$80	\$130
Hepatology Associate Member	\$80	\$130
Nonmember	\$115	\$165
Trainee Nonmember	\$85	\$135
Hepatology Associate Nonmember	\$85	\$135
Student	\$80	\$130

TICKETED ACTIVITIES



Hepatology Associates Course

Sunday, Nov. 9 • 8:00 am-1:30 pm

Course Directors: Anita Lippello, CRNP, NP-C, DNP; Donald Gardenier, DNP, FNP-BC

CME 5.5 CME Credits

CE 5.0 Contact Hours


Stay updated on new clinical guidelines for the management of hepatitis C and complications of liver disease by attending this comprehensive, patient-centered course. Advance your knowledge of evidence-based care, increase your comfort level in caring for patients with liver diseases, and improve patient outcomes as a result. Nurses, nurse practitioners, physician assistants, and other health care professionals will benefit from attending.

Upon completion of this activity, participants will be able to:

- State the new treatment regimens, and select the most appropriate medications.
- Identify potential side effects, and select appropriate management strategies.
- Effectively manage ascites in an outpatient setting.
- Distinguish when to use bacterial prophylaxis and how to treat infections.

	BEFORE 10/10	AFTER 10/10
Member	\$95	\$145
Nonmember	\$170	\$220
Student	\$95	\$145

TICKETED ACTIVITIES



Professional Development Workshop

Choices and Career Paths in Hepatology

Monday, Nov. 10 • 11:45 am–1:15 pm

Organizers: Susan L. Orloff, MD, FACS; Meena B. Bansal, MD; Kimberly D. Watt, MD; Marina G. Silveira, MD

CME Not Available

Explore the various career trajectories in the field of hepatology through a panel of speakers who will offer insight into the unique obstacles and opportunities each path brings. This activity is specifically designed for individuals who are either considering or already pursuing a hepatology-related career. Learn about successful career development strategies, examine women's professional needs, discuss strategies to improve work-life balance, and foster networking and mentoring opportunities.

Upon completion of this activity, participants will be able to:

- Compare the unique challenges and opportunities of the various career paths in hepatology.
- Develop strategies for academic and personal success.
- Identify new networking and mentoring opportunities.

	BEFORE 10/10	AFTER 10/10
Member	\$55	\$65
Nonmember	\$55	\$65



Program subject to change. Please confirm schedule in October through the “Liver Meeting” app, or onsite in the final printed Agenda.

AASLD ANNUAL MEETING

The AASLD Annual Meeting is part of The Liver Meeting®. Registration for the Annual Meeting includes:

- State-of-the-Art Lectures
- Poster, Plenary, and Parallel Sessions
- President’s Choice Lecture
- General Hepatology Update
- Global Forum
- Hepatitis Debrief
- HCV Symposium
- Emerging Trends Symposium
- Advances for Practitioners
- Maintenance of Certification (MOC) Session
- Competency Training Workshop
- Value-based Medicine in Hepatology
- Special Interest Group Programming
- Exhibit Hall Access
- One-Year Subscription to Online Content in *LiverLearning*®

Saturday - Tuesday, Nov. 8-11	BEFORE 10/10	AFTER 10/10
Member	\$100	\$200
Trainee Member	No charge	\$115
Hepatology Associate Member	\$100	\$200
Nonmember	\$465	\$565
Trainee Nonmember	\$205	\$305
Hepatology Associate Nonmember	\$205	\$305
Student	\$100	\$200

POSTER AND PLENARY SESSIONS



Poster Sessions

Saturday, Nov. 8–Tuesday, Nov. 11

Poster sessions provide an opportunity for authors to visually display and discuss their research. More than 2,000 basic science and clinical posters are scheduled for presentation.

SATURDAY, NOV. 8 <i>Presenters Available</i>	2:00–7:30 pm 5:30–7:00 pm
SUNDAY, NOV. 9 <i>Presenters Available</i>	8:00 am–5:30 pm 12:30–2:00 pm
MONDAY, NOV. 10 <i>Presenters Available</i>	8:00 am–5:30 pm 12:30–2:00 pm
TUESDAY, NOV. 11 <i>Presenters Available</i>	8:00 am–NOON 10:30 am–Noon

Plenary Sessions

Plenary sessions feature six didactic presentations representing the most outstanding scientific research submitted to AASLD. Presenters will have 10 minutes to discuss their research, followed by a 5-minute Q&A period.

SUNDAY, NOV. 9

8:00–9:30 am	Transplant Plenary I
10:30 am–Noon	Transplant Plenary II

MONDAY, NOV. 10

8:00–9:30 am	Basic Plenary
11:00 am–12:30 pm	Clinical Plenary

TUESDAY, NOV. 11

8:00–9:30 am	Hepatitis Plenary
--------------	-------------------

ePosters

Attendees can view the ePosters at stations located in the Hynes Convention Center. Browse abstracts by day, topic, author, and keyword; and leave comments and questions for the presenting author. ePosters will be available online after The Liver Meeting® 2014 through the LiverLearning® subscription included with your registration.

WORKSHOPS, LECTURES, AND SYMPOSIA

Competency Training Workshop

Friday, Nov. 7 • 12:30–2:45 pm

Course Directors: Oren K. Fix, MD, MS; Josh Levitsky, MD, MS

CME Not Available

Explore the knowledge and skills required to implement a competency-based transplant hepatology curriculum in both the traditional four-year and the pilot three-year programs. Program coordinators, program directors, clinical faculty members, and trainees in transplant hepatology, gastroenterology, and internal medicine in particular will find the workshop helpful. Presenters will review the revised Entrustable Professional Activities (EPAs) for transplant hepatology and discuss how clinical competency committees can use these and other assessment tools to inform the new ACGME reporting milestones. Transplant hepatology fellows will share their perceptions of the current training pathways.

Upon completion of this activity, participants will be able to:

- Identify the central components of transplant hepatology training in a traditional four-year track and a pilot three-year track, including the advantages and disadvantages of each pathway.
- List methods of assessment for transplant hepatology trainees, including EPAs and reporting milestones, and integrate them within the framework of clinical competency committees.
- Describe competency-based training in transplant hepatology from the fellow's perspective.



Program subject to change. Please confirm schedule in October through the “Liver Meeting” app, or onsite in the final printed Agenda.

WORKSHOPS, LECTURES, AND SYMPOSIA

Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture

Living Donor Liver Transplantation: Has It Fulfilled Its Promise?

Sunday, Nov. 9 • 9:30–10:00 am

Presenter: Jean C. Emond, MD

CME 0.5 CME Credits

Discover the latest news on the Living Donor Liver Transplantation (LDLT) program and become more confident in recommending and selecting patients for this intervention. The lecture seeks to raise awareness of the hepatology and surgical transplant communities by identifying the newest methods of liver donations, and to disseminate the latest approaches in recipient surgery.

Upon completion of this activity, participants will be able to:

- Review the history and establishment of LDLT.
- Demonstrate the worldwide clinical activity in LDLT.
- Identify obstacles to expand use of this therapy.
- Propose solutions and a vision for the future of LDLT.

Emerging Trends Symposium

Acute on Chronic Liver Failure

Sunday, Nov. 9 • 10:00–11:30 am

Moderators: Jasmohan S. Bajaj, MD; Patrick S. Kamath, MD

CME 1.5 CME Credits

Find out the latest about Acute on Chronic Liver Failure (ACLF), an increasingly identified yet poorly defined disease. Recognized by acute decompensation of the patient with cirrhosis and characterized by multiple organ failure, ACLF has a high mortality rate. Learn about the pathophysiology of ACLF, the role of infections as a precipitant, noninfectious causes, and promising therapies.

Upon completion of this activity, participants will be able to:

- Summarize the pathophysiology of ACLF.
- Discuss the role of infections and other precipitants of ACLF.
- Identify unique clinical issues in patients with ACLF.
- Explain the efficacy of investigational therapies for ACLF, including GCSF and bio-artificial liver support.

WORKSHOPS, LECTURES, AND SYMPOSIA

Hans Popper Basic Science State-of-the-Art Lecture

Induced Pluripotent Stem Cells and Their Use in the Study of Liver Disease and Development

Sunday, Nov. 9 • Noon-12:30 pm

Presenter: Stephen A. Duncan, DPhil

 0.5 CME Credits

Learn about the latest advancements in novel therapeutic approaches, including the use of patient-specific induced pluripotent stem cells (iPSCs) as a tool for the study of liver disease.

Upon completion of this activity, participants will be able to:

- Determine the advantages and disadvantages of using hepatocytelike cells derived from iPSCs to study errors of hepatic metabolism.

 New!

Value-based Medicine in Hepatology

Sunday, Nov. 9 • 1:00-3:00 pm

Moderators: Guadalupe Garcia-Tsao, MD; Mario Strazzabosco, MD, PhD

 2.0 CME Credits

Discover the concept of value-based medicine and the importance of returning the practice of hepatology to its appropriate focus: enabling the health and effective care of patients with liver disease. Get up to date on the value-based medicine program piloted by the University of Milan, and learn how a shift in the current quality movement can significantly impact the value of patient outcomes.

Upon completion of this activity, participants will be able to:

- Apply the concept of value-based medicine.
- Use the results of the pilot program in health outcomes in hepatology at the University of Milan.
- Impact health outcomes in the context of hepatology.

WORKSHOPS, LECTURES, AND SYMPOSIA

Keeping Up with Maintenance of Certification (MOC)

A Comprehensive Review of the ABIM MOC Program

Sunday, Nov. 9 • 1:15–2:45 pm

Organizers: Oren K. Fix, MD; Richard K. Sterling, MD; Mark W. Russo, MD

CME 1.5 CME Credits

ABIM certification is an important way to demonstrate to patients, members of the public, and other stakeholders that a physician has met rigorous standards within the six general competencies through self-assessment and evaluation. In addition, certification demonstrates one's commitment to continual professional development and lifelong learning. Recent changes to ABIM's Maintenance of Certification (MOC) requirements have left many confused and frustrated. This informational session is designed to provide hepatology physicians and trainees with an up-to-date overview of MOC requirements and the many steps in between to maintain certification.

Upon completion of this activity, participants will be able to:

- Describe current MOC requirements and highlight the recent changes.
- List the immediate steps needed to determine one's current status in MOC, enroll if not already enrolled, and determine what needs to be done before specific deadlines.
- Identify various ways to earn MOC points in both medical knowledge and practice assessment activities.
- Explain the MOC requirements and benefits to trainees early.

New!

Ethics and Humanities State-of-the-Art Lecture

A Toxic History of Modernity: From Black Bile to Living on Light

Sunday, Nov. 9 • 2:00–2:30 pm

Presenter: Iain Bamforth, MBChB, DLitt

CME 0.5 CME Credits

Explore the curious paradox that health (in spite of the World Health Organization's controversial definition of it as a condition of complete physical, mental, and social well-being) is actually a negative state. Being healthy means being hale or whole, but also being sublimely indifferent to our condition. Health happens unawares. On the other hand, being conscious about our healthiness may present the possibility of the self-consciousness itself becoming a sickness (hypochondria). Could it be that contemporary medicine and its instructions for living right is itself a sickness?

WORKSHOPS, LECTURES, AND SYMPOSIA

General Hepatology Update

Sunday, Nov. 9 • 3:00–4:30 pm

Moderators: Rohit Loomba, MD; Fred Poordad, MD

CME 1.5 CME Credits

Investigate the latest on clinical issues commonly seen in practice. Diagnostic strategies and approaches to management will be reviewed to provide state-of-the-art guidelines, particularly for diagnostic dilemmas.

Upon completion of this activity, participants will be able to:

- Apply the current guidelines for the diagnosis and management of hepatorenal syndrome.
- Review the current guidelines for the long-term care of liver transplant recipients.
- Identify the current guidelines for the diagnosis and management of autoimmune hepatitis.

Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture

Drug-Induced Liver Injury

Monday, Nov. 10 • 10:00–10:30 am

Presenter: Jay H. Hoofnagle, MD

CME 0.5 CME Credits

Keep up with the most current research, management, and prevention techniques in hepatotoxicity — the single major cause of acute liver failure in the U.S. Recent research findings provide insight on how to better care for patients and, for researchers, how to better understand the causes and mechanisms of injury in hepatotoxicity.

Upon completion of this activity, participants will be able to:

- Recognize different forms of drug-induced liver injury and distinguish between idiosyncratic and direct hepatotoxicity.
- Identify the major clinical presentations of drug-induced liver injury and how best to make the diagnosis and identify the causative agent.
- Evaluate the severity and prognosis of liver injury due to medications.

WORKSHOPS, LECTURES, AND SYMPOSIA

Advances for Practitioners

New Treatments for Hepatitis C

Monday, Nov. 10 • 11:00 am–12:30 pm

Moderator: Hugo R. Rosen, MD

CME 1.5 CME Credits

Review a comprehensive selection of recent publications on HCV infection with a panel of experts. Emphasis will be placed on understanding current and emerging regimens for the treatment of HCV, as well as identifying patients at risk of developing HCV-related hepatocellular carcinoma. Discussions from each study will address lessons learned, clinical context, and limitations.

Upon completion of this activity, participants will be able to:

- Discuss how to use sofosbuvir to treat chronic HCV infection.
- Discover new interferon-free and ribavirin-free regimens for the treatment of HCV infection.
- Determine which patients with HCV-related cirrhosis are at greater risk of developing hepatocellular carcinoma.

Global Forum

Health Disparities in Liver Disease: The Haves and Have-Nots

Monday, Nov. 10 • 2:00–4:00 pm

Moderators: Gyongyi Szabo, MD, PhD; Guadalupe Garcia-Tsao, MD

CME 2.0 CME Credits

Learn the aspects of health disparities in the worldwide public health epidemic of liver diseases among the five major regions of the world: North America, Europe, Latin America, Asia, and Africa. Speakers representing each region will discuss important issues on health disparities and/or barriers related to the epidemiology, diagnosis, and management of liver diseases. The discussion will address the most important public health problems regarding access to care, diagnosis, and treatments in each of these regions.

Upon completion of this activity, participants will be able to:

- Discuss the concept of health disparities as it relates to liver diseases.
- Recognize the regional disparities that may exist among North America, Europe, Latin America, Asia, and Africa.
- Identify steps to improve the care of patients with liver disease in populations with geographic or health disparities.

WORKSHOPS, LECTURES, AND SYMPOSIA

President's Choice Lecture

Four Decades of Progress in Hepatology

Monday, Nov. 10 • 2:15–2:45 pm

Presenter: Willis C. Maddrey, MD

 0.5 CME Credits

Take an in-depth look at the history of AASLD and the advancement of hepatology. Special emphasis will be placed on viral hepatitis, fatty liver, alcohol and drug-induced injury, and the evolution of liver transplantation.

Upon completion of this activity, participants will be able to:

- Recognize the rich history of AASLD and its role in hepatology.
- Discover how advancements in hepatology have occurred and their incorporation into practice.
- Predict where hepatology is headed in the next 50 years.

HCV Symposium

What's #Trending in Hepatitis C?

Monday, Nov. 10 • 4:45–6:15 pm

Moderators: Michael W. Fried, MD; Mark S. Sulkowski, MD

CME Not Available

Combinations of Direct-acting Antiviral Agents (DAAs) have achieved unprecedented cure rates of HCV infection. The tolerability and ease of administering these new regimens have the potential to expand treatment to many underserved populations and those with previously difficult-to-cure characteristics. Explore how to optimize current and future DAA regimens across diverse patient groups while discussing strategies for improving access to HCV care.

Upon completion of this activity, participants will be able to:

- Compare the strengths and limitations of all-oral regimens for HCV.
- Develop new strategies for maximizing access to HCV care across health care systems.
- Identify approaches to optimize outcomes in unique and difficult-to-cure populations.

WORKSHOPS, LECTURES, AND SYMPOSIA

Hepatitis Debrief

Tuesday, Nov. 11 • 9:45–10:30 am

Presenter: Michael W. Fried, MD

CME Not Available

This session will provide a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®.

Leon Schiff State-of-the-Art Lecture

Benign Tumors of the Liver

Tuesday, Nov. 11 • 10:30–11:00 am

Presenter: Jessica Zucman-Rossi, MD, PhD



0.5 CME Credits

Benign liver tumors are frequently difficult to diagnose in clinical practice. Recent identification of the different molecular classes of hepatocellular adenoma has enabled the development of new biomarkers useful in improving the diagnostic and prognostic assessment of these tumors. Keep on top of this molecular classification and learn how to initiate the process of new, personalized patient care.

Upon completion of this activity, participants will be able to:

- Identify the different types of benign hepatocellular tumors and their clinical, pathological, imaging, and epidemiological features.
- Review the molecular classification of hepatocellular adenoma.
- Evaluate how new molecular markers will improve the diagnostic and prognostic assessment of benign liver tumors.
- Translate molecular classification and improve personalized care of patients.

SPECIAL INTEREST GROUP (SIG) PROGRAMMING

AASLD's SIGs work collaboratively to shape the future of their specialized area of interest. A primary activity of the SIGs is to create educational content for programs within the AASLD Annual Meeting.

Interested in joining a SIG?

AASLD members—take advantage of this exclusive opportunity to network with colleagues in your area of interest. There are 13 SIGs to choose from, and no additional fee is required to join. Go to www.aasld.org/sig to learn more.

Liver Transplantation and Surgery SIG Program

Outreach in Liver Transplant

Saturday, Nov. 8 • 9:00 am–Noon

Course Directors: David C. Mulligan, MD, FACS; James F. Trotter, MD

CME Not Available

Experts from outreach programs across the country will examine a variety of issues linking outreach activity to program accomplishments, transplant referrals, and site selection. Plan to attend this didactic discussion and share your knowledge of best practices in establishing successful outreach programs.

Upon completion of this activity, participants will be able to:

- Measure the value of outreach in a liver transplant program.
- Develop, staff, and fund an outreach program.
- Assess the problems with the maturation of an outreach program.
- Integrate telemedicine into hepatology outreach.



Program subject to change. Please confirm schedule in October through the “Liver Meeting” app, or onsite in the final printed Agenda.

SPECIAL INTEREST GROUP (SIG) PROGRAMMING

Hepatotoxicity SIG Program

Pharmacogenomic Approaches in Drug-Induced Liver Injury (DILI) Research

Sunday, Nov. 9 • 4:45–6:45 pm

Moderators: Guruprasad P. Aithal, MD, PhD; Robert J. Fontana, MD

CME Not Available

DILI remains a vexing problem for clinicians, scientists, regulators, and drug developers due to its unpredictable nature and potential for significant morbidity and mortality. High-throughput, genomewide association chips and platforms provide unique tools to discover potential genetic associations for DILI and other rare ADRs. Recent studies have demonstrated strong and consistent associations in DILI susceptibility to individual drugs and various HLA alleles. Will the use of whole-genome or whole-exome approaches further facilitate the discovery of mechanistically relevant genetic associations? Learn the most current information on the use of pharmacogenomic approaches to DILI pathogenesis in this comprehensive program.

Upon completion of this activity, participants will be able to:

- Review the use of genomewide association chips and methods with susceptibility to DILI from individual agents.
- Improve the role of HLA polymorphisms in DILI susceptibility and potential molecular mechanisms.
- Apply epigenetic research principles to liver disease research, including DILI.

Hepatobiliary Neoplasia SIG Program

Primary Liver Carcinomas With Intermediate/Stem Cell Features: Microscopic to Genomic Evidence and Back

Sunday, Nov. 9 • 4:45–7:00 pm

Moderators: Morris Sherman, MBBCh, PhD, FRCP; Elizabeth M. Brunt, MD

CME Not Available

Addressing the need for a more widespread understanding of the pathways that lead to the development of hepatocellular carcinoma (HCC), this program will highlight the developments and current understanding of the role of stem cells in the development of HCC, and how this information may affect treatments.

Upon completion of this activity, participants will be able to:

- Discuss the pathogenesis of the development of intermediate forms of liver cancer, including those that have stem cell features.
- Recognize how pathology affects treatment decisions.

SPECIAL INTEREST GROUP (SIG) PROGRAMMING

Pediatric Liver Disease and Cholestatic Liver Disease Joint SIG Program **Controversies in the Management of Primary Sclerosing Cholangitis in Children and Adults**

Sunday, Nov. 9 • 4:45–7:00 pm

Moderators: Cara Mack, MD; David N. Assis, MD; Tom H. Karlsen, MD, PhD

CME Not Available

Primary Sclerosing Cholangitis (PSC) is a progressive biliary disease that affects children and adults, often resulting in liver transplantation. The cause of PSC is not understood and there are no effective therapies for the disease. Furthermore, a difference in clinical presentation and treatment exists between children and adults, and hepatologists from both fields have the potential to gain insight into the disease through understanding these differences. Find out about recent areas of advancement and debate in PSC. This program is distinctive in that PSC experts from both pediatrics and adult care will converge to discuss controversies in managing PSC, resulting in the identification of new research avenues and opportunities.

Upon completion of this activity, participants will be able to:

- Discuss how the pediatric patient may be managed differently than adults.
- Discover cutting-edge genetic and microbiome research that provides evidence for PSC pathogenesis and susceptibility.
- Identify controversies related to the diagnosis and treatment of cholangiocarcinoma and post-liver transplant recurrent PSC.
- Explain potential PSC treatment options.

SPECIAL INTEREST GROUP (SIG) PROGRAMMING

Liver Cell Biology in Hepatic Disease and Liver Fibrosis Joint SIG Program

The Cell Biology of Hepatic Disease

Sunday, Nov. 9 • 4:45-7:45 pm

Moderators: Mark A. McNiven, PhD; Natalie Torok, MD; Allan W. Wolkoff, MD; Natalia Nieto, PhD; Yasuko Iwakiri, PhD; Mohammed Anwer, PhD

CME Not Available

The central functions of the liver are maintained by essential cell biological processes performed by parenchymal, ductular, and other supportive cells. These important processes are supported by intricate and elaborate receptor signaling cascades, cytoskeletal networks, vesicular trafficking pathways, cell surface transporters, and extra-cellular adhesion complexes. These components all must function with synergistic precision, and any disruption can lead to cancer, fibrosis, steatosis, or cholestasis. Further, these processes can be usurped by many pathogens to promote invasive life cycles — leading to viral hepatitis and other infectious diseases. Delve into the basic cell biological functions of hepatic cells for a greater understanding of their relational consequences.

Upon completion of this activity, participants will be able to:

- Gain a greater understanding of basic cell biological functions of hepatic cells such as protein and lipid traffic, cytoskeletal organization, cellular polarity, and receptor signaling cascades in health and disease. Pathological changes in cellular functions can translate into modulation of trafficking, cell adhesion, and matrix production, leading to liver damage, cholestasis, and fibrogenic signals.
- Discuss how central processes are altered and tailored to suit the highly specialized functions of the liver, including regeneration, bile formation, endocytic-based filtering of the blood, secretion of essential plasma proteins, and regulation of the extracellular matrix.
- Identify how hepatocellular functions are usurped and modified in hepatic diseases such as liver fibrosis and cancer.

SPECIAL INTEREST GROUP (SIG) PROGRAMMING

Portal Hypertension SIG Program

Noninvasive Methods to Stratify Risk in Patients With Compensated Cirrhosis Portal Hypertension

Monday, Nov. 10 • 4:45–6:45 pm


Moderators: **Guadalupe Garcia-Tsao, MD; Juan-Carlos Garcia-Pagan, MD**

CME Not Available

There is a clinical need for the development of new noninvasive prediction tools that can divide patients with compensated cirrhosis into those requiring intensive follow-up and those for whom follow-up can be lengthened. Learn from clinicians and investigators working in the area of cirrhosis and portal hypertension and those studying new noninvasive biological markers (“omics”) and imaging. Course moderators will identify key questions and technologies for risk stratification and understanding mechanisms of decompensation in compensated cirrhosis.

Upon completion of this activity, participants will be able to:

- Identify the current knowledge and needs regarding risk stratification in patients with compensated cirrhosis.
- Review potential noninvasive breakthrough technologies that might add to current knowledge of outcomes prediction and expand knowledge of the mechanisms of decompensation and/or HCC.
- Recognize opportunities for using new technologies to identify and modulate mechanisms involved in deterioration in compensated cirrhosis.



Program subject to change. Please confirm schedule in October through the “Liver Meeting” app, or onsite in the final printed Agenda.

SPECIAL INTEREST GROUP (SIG) PROGRAMMING

Liver Fibrosis SIG and Steatosis and Steatohepatitis SIG Joint Program Immunity and Lipids as New Drivers in Inflammation and Fibrosis of Nonalcoholic Steatohepatitis

Monday, Nov. 10 • 4:45–7:00 pm

Moderators: Frank A. Anania, MD; Nicholas O. Davidson, MD

CME Not Available

Examine the basic mechanisms of NASH progression and the regulation of fibrogenesis in advanced NASH in this joint SIG program. Divided into subsections, the program covers the immunological aspects of NASH and the role of gut dysbiosis. Extending from these will be presentations on how fibrogenic processes are regulated by the localization of lipid stores, and an emphasis on the regulation of lipogenesis as it relates to liver fibrosis. The program provides a unique perspective on how cellular processes are connected during NASH.

Upon completion of this activity, participants will be able to:

- Explain the role of both the innate and acquired immune system in the development of inflammation in fatty liver disease, and as a consequence of changes in gut microbiota (dysbiosis).
- Discuss the role of lipids as pro-fibrogenic molecules and how the localization of lipid stores enhances the mechanisms of fibrogenesis.
- Develop collaborations between the two SIGs, resulting in future translational and clinical studies.



SPECIAL INTEREST GROUP (SIG) PROGRAMMING

Acute on Chronic Liver Failure SIG Program

Renal Dysfunction in Cirrhosis: Should We Change the Way We Manage These Patients?

Monday, Nov. 10 • 4:45–7:30 pm

Moderators: Florence Wong, MD; Paolo Angeli, MD

CME Not Available

Are milder cases of renal dysfunction simply occurring at an earlier stage of the natural history of cirrhosis, or do they have a different pathophysiology? The process of determining how to prevent and manage renal dysfunction is still not well-defined. Review the most current findings on renal dysfunction in cirrhosis with a special focus on clinical practice, and learn the latest on the pathophysiology and treatment options that will bring bench to bedside.

Upon completion of this activity, participants will be able to:

- Review the inadequacies of the different measures of renal function in cirrhosis.
- Explain the rationale for needing to redefine renal dysfunction in cirrhosis.
- Compare the treatment options for renal dysfunction in cirrhosis, including liver transplantation.

Hepatitis B SIG Program

The Next Generation of HBV Therapy: From Discovery to Cure

Monday, Nov. 10 • 4:45–7:50 pm

Moderators: T. Jake Liang, MD; Timothy M. Block, PhD

CME Not Available

Chronic hepatitis B infection is associated with a significant risk of liver cirrhosis and hepatocellular carcinoma. There are now seven approved medications to manage chronic hepatitis B, but these require indefinite periods of use and are not indicated for all chronic hepatitis B patients. Moreover, these medications reduce the risk of death due to liver disease by only 50 to 60 percent after 10 years of use. Learn about new therapeutics that complement or improve on the current portfolio. Management of patients with chronic hepatitis B and the discovery of new liver disease therapies are centrally responsive to the AASLD mission. This session will address these issues through colloquia.

Upon completion of this activity, participants will be able to:

- Predict the next wave of HBV therapeutics.
- Employ hepatitis research programs and stimulate interest in collaborative studies.
- Discuss the status of new HBV drugs in the development pipeline.

Program subject to change. Please confirm schedule in October through the “Liver Meeting” app, or onsite in the final printed Agenda.

AASLD PAVILION

Friday, Nov. 7 – Tuesday, Nov. 11

AASLD moves hepatology forward in patient care and research advances. Join us, or renew your membership, while you're in Boston. Visit the AASLD Pavilion — just outside Hall A in the Hynes

Convention Center — to learn about the benefits of membership, download practice guidelines, try our online learning programs, and more.



EXHIBIT HALL

Saturday, Nov. 8—Monday, Nov. 10

More than 60 companies will be present in the exhibit hall and give you access to the latest products, services, and technology relative to hepatology. From the opening reception to daily coffee breaks, this important component of The Liver Meeting® 2014 extends networking beyond the sessions.


Exhibitors

(as of July 1, 2014)

AbbVie
 AcariaHealth
 Accredo
 Advanced Biological Laboratory
 Alpha-1 Foundation
 American Liver Foundation
 American Porphyria Foundation
 Asian Pacific Association for the Study of the Liver
 Baxter Gambro
 BioPlus Specialty Pharmacy
 BriovaRx
 Bristol-Myers Squibb
 BTG
 China Novartis Institutes for BioMedical Research Co., Ltd.
 The Cholangiocarcinoma Foundation
 Chronic Liver Disease Foundation
 Clinical Care Options
 The Cochrane Hepato-Biliary Group
 Corgenix Inc.
 CTI Clinical Trial and Consulting Services
 CVS/Caremark Specialty Pharmacy
 Digestive Disease Week
 Duke Clinical Research Institute
 Echosens
 Elsevier Inc.
 European Association for the Study of the Liver
 Galmed Pharmaceutical, Ltd.
 Gastroenterology and Endoscopy News
 Gastroenterology and Hepatology

GI Supply
 Gilead Sciences, Inc.
 Gore and Associates
 Ikaria
 Intercept Pharmaceuticals
 International Association for the Study of the Liver
 Janssen Global Services LLC
 LabCorp
 Maxor Specialty
 Merck
 Onyx Pharmaceutical/Bayer Healthcare
 OraSure Technologies
 Oxford University Press
 Patient Access Network Foundation
 Perspectum Diagnostics Ltd.
 PhoenixBio USA Corporation
 PRA
 PSC Partners Seeking a Cure
 Quest Diagnostics
 Salix Pharmaceuticals, Inc.
 Sanofi (Beijing) Pharmaceuticals Co. Ltd.
 SC Liver Research Consortium, LLC
 Slack, Inc.
 SuperSonic Imagine
 Target Specialty Pharmacy
 University of Pittsburgh
 US Bioservices Specialty Pharmacy
 Vital Therapies, Inc.
 Wako Diagnostics
 Walgreens Specialty Pharmacy
 Wiley
 World Hepatitis Alliance
 World Hepatitis Fund

Saturday, Nov. 8	
5:00–7:30 pm	Exhibit opens
5:00–7:30 pm	Opening reception
Sunday, Nov. 9	
9:30 am–3:00 pm	Exhibit hall hours
10:00–10:30 am	Coffee break
1:30–2:00 pm	Snack break
Monday, Nov. 10	
9:30 am–3:00 pm	Exhibit hall hours
10:00–10:30 am	Coffee break
1:30–2:00 pm	Snack break



Program subject to change. Please confirm schedule in October through the “Liver Meeting” app, or onsite in the final printed Agenda.

CONTINUING EDUCATION INFORMATION

Continuing Medical Education (CME)


Accreditation Statement

The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

AASLD designates these live activities for *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Maximum credit hours for each designated portion of the meeting are:

Annual Meeting Activities	20.5 CME Credits
Postgraduate Course	12.0 CME Credits
Basic Research Workshop	4.0 CME Credits
Hepatology Associates Course	5.5 CME Credits
AASLD/ILTS Transplant Course	6.5 CME Credits*
AASLD/ASGE Endoscopy Course	7.0 CME Credits**
Transplant Surgery Workshop	3.5 CME Credits
AASLD/NASPGHAN Pediatric Symposium	3.0 CME Credits**

 denotes CME Credit

As an accredited provider, AASLD ensures the content of all CME activities and related materials will promote improvements or quality in health care, and are not a specific proprietary business interest of a commercial interest. As such, some sessions or ticketed activities may not offer CME credits.

*This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplant Society (ILTS). AASLD is accredited by the ACCME to provide continuing medical education for physicians.

**Co-sponsored activities – AASLD is accredited by ACCME to provide continuing medical education for physicians.

Target Audience

Groups include clinical hepatologists, gastroenterologists, other health care providers (midlevel providers, internists, pediatricians, family practitioners), and trainees (students, residents, and specialty fellows). The target audience also encompasses scientists studying the development, physiology, pathology, translational medicine, and clinical trials related to the liver and biliary tract and liver transplantation.

Learning Objectives of The Liver Meeting® 2014

Upon participation in this live educational activity, learners will be able to:

- Incorporate new scientific evidence into clinical care protocols and improve the outcome of adults and children with acute and chronic diseases of the liver and biliary tract.
- Establish new collaborations, implement new clinical trials, develop comparative effectiveness projects, and complete investigative efforts that will improve the outcome of adults and children with acute and chronic diseases of the liver and biliary tract.
- Implement effective care plans to improve the long-term outcome of the transplanted patient.

CONTINUING EDUCATION INFORMATION


Continuing Education (CE)

The Institute for the Advancement of Human Behavior is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The following ticketed activities will award nurse CE contact hours:

- AASLD/ILTS Transplant Course: 5 contact hours
- Postgraduate Course: 10 contact hours
- Hepatology Associates Course: 5 contact hours

These activities are co-provided by IAHB and AASLD. Maximum **20 contact hours**.

 denotes CE Credit

Claiming CME/CE Credit and Certificates of Attendance

The CME/CE evaluations are electronic and can be completed in the following ways:

- Use the "Liver Meeting" app to evaluate the sessions in real time. Search "Liver Meeting" in the App Store (for your Apple device) or in Google Play (for your Android device.)
- Access the evaluation website using your personal device of choice. A link to the CME and CE evaluation websites will be available on The Liver Meeting® website.
- Visit Tech Connect to access the evaluation from any available kiosk.

CME and CE credit will be awarded when you complete the electronic evaluation. You can download and/or print a certificate for your records once you have completed the CME and/or CE evaluations.

Certificates of Attendance are also available. They may be downloaded and/or printed after completing The Liver Meeting® evaluation.

GENERAL INFORMATION

Disclosure Policy

It is AASLD's policy to ensure balance, independence, objectivity, and scientific rigor in all of its individually or jointly sponsored educational programs. Individuals in a position to control the content of an AASLD-sponsored activity (program planners, course directors, speakers, and others) are expected to disclose all relevant financial relationships during the past 12 months. AASLD will identify and resolve all conflicts of interest prior to program implementation.

In addition to written disclosure, presenters will disclose any vested interest and/or their intention to discuss off-label use of pharmaceuticals or devices, if applicable, to the audience at the beginning of their presentation and in accordance with ACCME standards and Food and Drug Administration requirements.

Schedule Subject to Change

Schedule, speakers, and course descriptions are subject to change. For current information, go to www.aasld.org.

Use of AASLD Scientific Program Content

Information presented during The Liver Meeting® is the property of AASLD and the presenter. Information may not be recorded, photographed, copied, photocopied, transferred to an electronic format, reproduced, or distributed without the written permission of AASLD and the presenter. Any use of the program content, which includes, but is not limited to, oral presentations, audiovisual materials used by speakers, and program handouts, without AASLD's written consent is prohibited.

Abstract Embargo Policy

Accepted abstracts are made available to the public on the AASLD website and are published in the October supplement of HEPATOLOGY. Information contained in those abstracts may not be released until they appear on the AASLD website. Academic institutions, private organizations, and companies with products whose values may be influenced by information contained in an abstract may issue a news release to coincide with the availability of an abstract on AASLD's website. However, information beyond that contained in the abstract, e.g., discussion of the abstract done as part of a scientific presentation or presentation of additional or new information that will be available at the time of the meeting, is embargoed from release to the general public until the first day of The Liver Meeting®.

The release of information prior to this day violates AASLD's Abstract Embargo Policy, and in the event information from an abstract is released, that abstract is subject to withdrawal from The Liver Meeting® program. Authors are responsible for notifying financial and other sponsors of this policy.

AASLD may allow for exceptions, on a case-by-case basis, to the Abstract Embargo Policy for compelled disclosures mandated by federal securities laws. However, AASLD requires the company president, general counsel, or other appropriate official of a company seeking such an exception to attest in writing to the specific facts in support of the request, including exactly how the securities laws are implicated, with statutory citation(s). General statements of

GENERAL INFORMATION

the need to comply with the law will not be considered sufficient. Requests for an exception must be sent to the AASLD CEO. AASLD requires a minimum of five days from receipt of the request to evaluate the request. In granting an exception, the AASLD requires the company to state in its public disclosure that the complete and final results will be presented at The Liver Meeting®. The AASLD will also require the inclusion of unreleased and unique data in such a presentation at The Liver Meeting®.

Public release of a journal article relevant to the abstract will be considered an exception to the Abstract Embargo Policy if at the time of the abstract submission deadline, the decision concerning the manuscript was not revealed to the authors.

Limited License

The Liver Meeting® is protected by copyright, trademark, and/or other applicable laws. Any use of “The Liver Meeting®,” including recordings and the development of derivative works, is prohibited. The name, logo, and acronym of the American Association for the Study of Liver Diseases and The Liver Meeting® are the exclusive property of and are trademarked by AASLD. They may not be used in any way, for any purpose, or at any time (including but not limited to announcements, invitations, emails, and Web publications) without the express written permission of AASLD.

View complete guidelines on the AASLD website: www.aasld.org.